Insulet (PODD)
(Delayed Data from NSDQ)
$235.43 USD
-3.37 (-1.41%)
Updated Sep 26, 2024 03:57 PM ET
After-Market: $235.71 +0.28 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$235.43 USD
-3.37 (-1.41%)
Updated Sep 26, 2024 03:57 PM ET
After-Market: $235.71 +0.28 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Zacks News
Here's Why You Should Buy Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG), owing to product launches and the performance of segments.
Tandem Diabetes (TNDM) Avails Tandem Source in the United States
by Zacks Equity Research
Tandem Diabetes (TNDM) announces the full U.S. launch of Tandem Source, a new diabetes management platform for customers and healthcare providers.
Integra (IART) to Advance ENT Division With New Buyout Deal
by Zacks Equity Research
Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.
Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes
by Zacks Equity Research
Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.
Medtronic (MDT) Expands AI-Driven Care With New Partnership
by Zacks Equity Research
Medtronic's (MDT) expanded collaboration with Cosmo Pharmaceuticals is a strategic step forward in its quest to use AI to improve patient care.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.
Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.
QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes
by Zacks Equity Research
QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.
Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space
by Zacks Equity Research
Terumo's (TRUMY) coil system boasts a soft, universal-shaped platinum and hydrogel composition, which sets it apart in the peripheral coil market.
Charles River (CRL) Expands 3D In Vitro Services Via New Deal
by Zacks Equity Research
Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) due to the sustained growth in the SaaS business.
Thermo Fisher (TMO) Launches New Solutions for Clinical Labs
by Zacks Equity Research
Thermo Fisher (TMO) introduces the KingFisher Apex Dx system and Applied Biosystems MagMAX Dx Isolation Kit to improve preanalytical workflows for clinical laboratories.
Edwards Lifesciences (EW) Forwards Growth Strategy and Outlook
by Zacks Equity Research
Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.
Illumina (ILMN) Expands Globally Despite Macroeconomic Woes
by Zacks Equity Research
The NovaSeq X launch strengthens Illumina's (ILMN) competitive position in high-throughput sequencing.
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
If You Invested $1000 in Insulet a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Walgreens' (WBA) AllianceRx Pharmacy Will Now Distribute XDEMVY
by Zacks Equity Research
Walgreens' (WBA) subsidiary, AllianceRx Walgreens Pharmacy, is one of the four specialty pharmacies selected to distribute XDEMVY.
Centene's (CNC) Ambetter Enhances Offerings With Broward Health
by Zacks Equity Research
Centene's (CNC) Health Insurance Marketplace brand Ambetter strengthens its provider network with Broward Health.
BrainsWay (BWAY) Strengthens South Korean Foothold With Deep TMS
by Zacks Equity Research
BrainsWay's (BWAY) Deep TMS targets affected brain structures with a magnetic field, stimulating crucial neural networks.
Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden
by Zacks Equity Research
Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.
Centene (CNC), Mindoula to Address Mental Health Issues in Indiana
by Zacks Equity Research
Centene's (CNC) unit, MHS, collaborates with Mindoula to enhance mental health support for Hoosiers and attract more customers to opt for CNC's Medicaid plans.
Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay
by Zacks Equity Research
Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing
by Zacks Equity Research
OrthoPediatrics (KIDS) continues to diversify its non-surgical offerings with the introduction of the DF2 Brace.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and a favorable liquidity structure.